Canada: Canada’s Clinical Trial Infrastructure: A National Framework For Coordinating Clinical Trials

Last Updated: December 28 2012
Article by Christelle Gedeon and Joanie Lapalme

The Standing Senate Committee on Social Affairs, Science and Technology released a report in November (2012) entitled Canada's Clinical Trial Infrastructure: A Prescription for Improved Access to New Medicines, which paints a dreary picture of the health of the Canadian pharmaceutical R&D landscape. The report indicates that Canada is losing its ability to attract clinical trials by pharmaceutical innovators. This decline in clinical trial activity is expected to translate into lost opportunities for Canada in drug innovation. The report proposes a standardized approach to research ethics review and the reporting of data in an open and transparent process as a step stone to resolving the issue. These changes are expected to significantly impact the time required to launch clinical trials and help Canada reclaim a competitive edge.

The report is the first phase of a four-part study aiming at examining and reporting on prescription pharmaceuticals in Canada. Over the course of eleven (11) meetings, from March 28 to May 30, 2012, the Committee heard testimony from Health Canada, the Office of the Auditor General of Canada, representatives from the pharmaceutical and clinical trial industries, patient advocacy groups, medical, ethical and legal academics and representatives of research ethics boards. The report makes 12 recommendations that address issues such as: enhanced leadership of the federal government; transparency of the clinical trial process; standards and accreditation of research ethics review; barriers to patient recruitment; inclusion of vulnerable sub-groups of the population; drugs for rare diseases and the need to assess patent protection and tax incentives.

The primary objective of the report is to provide recommendations to the federal government that may position Canada more favourably on the global stage as a preferred jurisdiction for clinical trials. Among the first recommendations is the creation of a National Framework for Coordinating Clinical Trials. At the moment, clinical trials for the same pharmaceutical entity are performed in silos. Each site operates independently. Sites are limited to their patient population and are restricted to the ethics review within their own institution. The creation of a National Framework is expected to promote the importance of new clinical trials and the benefits of being a participant to the individual and to the community at large. Most importantly, it is intended as a point of contact between the pharmaceutical industry and the research community for sharing experiences with patient recruitment, treatment and clinical outcomes.

Second, the report recommends improving the lack of transparency and the need for increased public disclosure about ongoing clinical trials. This is particularly a concern for patient advocacy groups and health care professionals. The registration of clinical trial data on a publicly accessible database would help providers make informed decisions and would increase access to new medicines for patients seeking alternative options. It would also allow academics to perform a comprehensive analysis of trial data, producing more valuable risk-benefit profiles for new therapies. Foreign clinical trial data used to support submissions for drug approval in Canada should also be registered in order to better inform the strict risk-based approach employed by Health Canada in approving drugs for sale in the Canadian marketplace.

Third, the report calls for the standardization of the research ethics review process and the accreditation of research ethics boards. Originally, research ethics boards were created within academic institutions. Over time, many trials for new drugs have moved into the community and are led by community based physicians or contract research organizations. As such, ethical review of clinical trials varies among research centers. Most, if not all clinical trial sites establish their own research ethics review board and operate under their own guidelines. An accreditation process is proposed as a method of improving the lack of consistency among ethics boards. Accreditation would impose a uniform set of rules for the approval of clinical trials in Canada. 

To complement the changes to the clinical trial regime, the report further called for changes to the drug regulatory regime. The recommended changes would require that clinical trial design reflect the population that can reasonably be expected to consume the drug once it is on the market. For example, where drugs are specifically designed for use in pregnancy, a population of pregnant patients should be included in the clinical design. Consequently, market approval should only be granted by Health Canada if clinical trial data is available about all relevant population sub-groups.

Finally, the issue of rare diseases and the need for specific policy measures aimed at encouraging drug development and improved drug access for patients with rare diseases (an Orphan Drug Policy), were also examined. The hope is that the recent creation of the Orphan Drug Framework will encourage research and development as well as facilitate authorization of new drugs. The hope is that the framework will promote Canada as a preferred site for conducting clinical trials for orphan drugs and facilitate the work of stakeholders to develop strategies for maximizing patient recruitment into such trials.

Canada's ability to attract life science investment from major pharmaceutical innovators has been critical in maintaining the infrastructure of the medical system and keeping Canada at the forefront of medical innovation. This report is an indication that Canada has set its eyes on regaining its competitive edge on the world stage as a destination for investment and innovation in medicine.

This report is the first phase of a four-part study on medical research and innovation; we will keep you informed of the next three phases which will discuss the post-approval monitoring of prescriptions pharmaceuticals, the off-label use of prescription pharmaceuticals, and the nature of the unintended consequences in the use of prescription pharmaceuticals.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions